Introduction: Common approaches in cost-effectiveness analyses do not adjust for confounders. In nonrandomized studies this can result in biased results. Parametric models such as regression models are commonly applied to adjust for confounding, but there are several issues which need to be...

Cost-effectiveness analysis is versatile and used widely to assist in health care decision making. This chapter discusses how cost-effectiveness analysis is used at the system or national level, particularly in the domain of coverage and payment policy. We describe its relationship to other...

This paper examines empirically the determinants of COVID-19 vaccine rollouts and their effects on health outcomes. We assemble a comprehensive and novel cross-country database at a daily frequency on vaccinations and various health outcomes (new COVID-19 cases, fatalities, intensive care unit...

Cost-effectiveness analysis often plays an important role in prioritization among different types of public health expenditures. Cost-effectiveness is defined as the maximal health benefits for given expenditures on health care. With a private health sector as a supplement to the public sector,...

Background: The Fracture Intervention Trial (FIT) showed that the bisphosphonate alendronate reduces the risk of fractures in women with low bone mass in the United States. Objective: To estimate the cost-effectiveness (cost per life-year gained and cost per quality-adjusted life-year, QALY,...

Millions Saved (2016) is a new edition of detailed case studies on the attributable impact of global health programs at scale. As an input to the book, this paper provides an independent assessment of the cost-effectiveness of a selection of the cases using ex post information from impact...

Aims: To aid public health policymaking, we studied the cost-effectiveness of buprenorphine, naltrexone, and placebo interventions for heroin dependence in Malaysia. Design: We estimated the cost-effectiveness ratios of three treatments for heroin dependence. We used a microcosting methodology...

Objective: To estimate the cost-effectiveness for Colombia of four asymptomatic-bacteriuria (ABU) screening alternatives in pregnant women: a) urine culture, b) Gram stain, c) urianalysis and d) urianalysis followed by urine culture after a positive result.Methods: Two decision trees were built...

Methods: A decision tree model was built with life years gained as outcome, from the perspective of the health system, and including all direct costs. Pharmaceutical prices were obtained from the System of Information of Medicaments SISMED (2008), and the value of procedures was calculated from...